Drug giant Merck is to acquire biopharmaceutical company Idenix for $24.50 per share, valuing the purchase at around $3.85 billion.
Irish-based drug manufacturer Actavis has settled its patent dispute with Zydus Pharmaceuticals.
Law firm Dechert LLP has appointed Rüdiger Herrmann as a partner in its Frankfurt office.
AMAG Pharmaceuticals, Inc. has had a US patent covering ferumoxytol extended.
Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.
Pharmaceutical professionals should have a “wide-ranging” debate on how IP can be tailored in the face of “major changes” to the industry, including the possibility of “prolonged exclusivity” for certain medicines, according to a report.
Pfizer and Mylan have agreed to settle litigation related to arthritis treatment Celebrex (celecoxib), Mylan announced today, June 2.
A pharmaceutical company in Turkey has run into trouble after attempting to register the Turkish word for ‘pharmacist’ as a trademark.
Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.
Justice Colin Birss has refused Roche’s biotechnology subsidiary Genentech the permission to appeal against an English High Court decision in which two patents covering its blockbuster breast cancer drug, Herceptin (trastuzumab), were revoked.